A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts

Maiko Matsushita, Yoshie Ozaki, Yuka Hasegawa, Fukiko Terada, Noriko Tabata, Hirokazu Shiheido, Hiroshi Yanagawa, Tsukasa Oikawa, Koichi Matsuo, Wenlin Du, Taketo Yamada, Masashi Hozumi, Daiju Ichikawa, Yutaka Hattori

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

January Despite the recent advances in the treatment of multiple myeloma (MM), MM patients with high-risk cytogenetic changes such as t(4;14) translocation or deletion of chromosome 17 still have extremely poor prognoses. With the goal of helping these high-risk MM patients, we previously developed a novel phthalimide derivative, TC11. Here we report the further characterization of TC11 including anti-myeloma effects in vitro and in vivo, a pharmacokinetic study in mice, and anti-osteoclastogenic activity. Intraperitoneal injections of TC11 significantly delayed the growth of subcutaneous tumors in human myeloma-bearing SCID mice. Immunohistochemical analyses showed that TC11 induced apoptosis of MM cells in vivo. In the pharmacokinetic analyses, the Cmax was 2.1 μM at 1 h after the injection of TC11, with 1.2 h as the half-life. TC11 significantly inhibited the differentiation and function of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated osteoclasts in mouse osteoclast cultures using M-CSF and RANKL. We also revealed that TC11 induced the apoptosis of myeloma cells accompanied by α-tubulin fragmentation. In addition, TC11 and lenalidomide, another phthalimide derivative, directly bound to nucleophosmin 1 (NPM1), whose role in MM is unknown. Thus, through multiple molecular interactions, TC11 is a potentially effective drug for high-risk MM patients with bone lesions. The present results suggest the possibility of the further development of novel thalidomide derivatives by drug designing.

Original languageEnglish
Article numbere0116135
JournalPloS one
Volume10
Issue number1
DOIs
Publication statusPublished - 2015 Jan 24

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Fingerprint Dive into the research topics of 'A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts'. Together they form a unique fingerprint.

  • Cite this

    Matsushita, M., Ozaki, Y., Hasegawa, Y., Terada, F., Tabata, N., Shiheido, H., Yanagawa, H., Oikawa, T., Matsuo, K., Du, W., Yamada, T., Hozumi, M., Ichikawa, D., & Hattori, Y. (2015). A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts. PloS one, 10(1), [e0116135]. https://doi.org/10.1371/journal.pone.0116135